Literature DB >> 18508629

HPV-16 RNA processing.

Stefan Schwartz1.   

Abstract

To understand human papillomavirus type 16 (HPV-16) gene regulation, it is necessary to understand HPV-16 RNA processing. HPV-16 encodes multiple 5'- and 3'-splice sites and two polyadenylation signals pAE and pAL (Figure 1). The major 3'-splice site on the HPV-16 genome (SA3358) is used for generation of E6, E7, E4, L1 and L2 mRNAs. It encodes a suboptimal splice signal but is under control of a strong enhancer that renders SA3358 one of the most efficiently used splice sites on the HPV-16 genome. Thereby SA3358 indirectly blocks HPV-16 late gene expression. The early polyA signal is also under control of the early UTR sequence and multiple RNA elements in the L2 coding region that interact with hnRNP H. The two splice sites SD3632 and SA5639 are used exclusively by late mRNAs and are under control of multiple splicing silencer elements. The silencers at SA5639 are located in the L1 coding region and interact with hnRNP A1. So far, only polypyrimidine tract binding protein (PTB) has been shown to induce late gene expression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18508629     DOI: 10.2741/3123

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  19 in total

Review 1.  Persistence of human papillomavirus infection: keys to malignant progression.

Authors:  Jason Bodily; Laimonis A Laimins
Journal:  Trends Microbiol       Date:  2010-11-01       Impact factor: 17.079

2.  Alternative splicing of human papillomavirus type-16 E6/E6* early mRNA is coupled to EGF signaling via Erk1/2 activation.

Authors:  Simone Rosenberger; Johanna De-Castro Arce; Lutz Langbein; Renske D M Steenbergen; Frank Rösl
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

3.  HPV-16 E2 contributes to induction of HPV-16 late gene expression by inhibiting early polyadenylation.

Authors:  Cecilia Johansson; Monika Somberg; Xiaoze Li; Ellenor Backström Winquist; Joanna Fay; Fergus Ryan; David Pim; Lawrence Banks; Stefan Schwartz
Journal:  EMBO J       Date:  2012-05-22       Impact factor: 11.598

4.  Multiple ASF/SF2 sites in the human papillomavirus type 16 (HPV-16) E4-coding region promote splicing to the most commonly used 3'-splice site on the HPV-16 genome.

Authors:  Monika Somberg; Stefan Schwartz
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

Review 5.  Regulation of human papillomavirus gene expression by splicing and polyadenylation.

Authors:  Cecilia Johansson; Stefan Schwartz
Journal:  Nat Rev Microbiol       Date:  2013-03-11       Impact factor: 60.633

6.  Analysis of transcripts from predicted open reading frames of Musca domestica salivary gland hypertrophy virus.

Authors:  Tamer Z Salem; Alejandra Garcia-Maruniak; Verena-U Lietze; James E Maruniak; Drion G Boucias
Journal:  J Gen Virol       Date:  2009-03-04       Impact factor: 3.891

7.  The E8--E2 gene product of human papillomavirus type 16 represses early transcription and replication but is dispensable for viral plasmid persistence in keratinocytes.

Authors:  Michael J Lace; James R Anson; Gregory S Thomas; Lubomir P Turek; Thomas H Haugen
Journal:  J Virol       Date:  2008-08-27       Impact factor: 5.103

8.  Intron definition and a branch site adenosine at nt 385 control RNA splicing of HPV16 E6*I and E7 expression.

Authors:  Masahiko Ajiro; Rong Jia; Lifang Zhang; Xuefeng Liu; Zhi-Ming Zheng
Journal:  PLoS One       Date:  2012-10-04       Impact factor: 3.240

Review 9.  Converging strategies in expression of human complex retroviruses.

Authors:  Ilaria Cavallari; Francesca Rende; Donna M D'Agostino; Vincenzo Ciminale
Journal:  Viruses       Date:  2011-08-11       Impact factor: 5.048

10.  Characterization of Mus musculus papillomavirus 1 infection in situ reveals an unusual pattern of late gene expression and capsid protein localization.

Authors:  Alessandra Handisurya; Patricia M Day; Cynthia D Thompson; Christopher B Buck; Yuk-Ying S Pang; Douglas R Lowy; John T Schiller
Journal:  J Virol       Date:  2013-09-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.